LIVER INTERNATIONAL-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2156049, encodeId=ced021560498b, content=这个杂志投稿之后很快就变成under review状态，有两个编辑名字，这是送外审了还是编辑初审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e57d5450113, createdName=ms4000002019232997, createdTime=Mon Sep 04 16:33:05 CST 2023, time=2023-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交 10-10 拒稿 第一个审稿人完全否定 第二个审稿人列出了大量的建议 副主编也给出了一条建议 总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226326, encodeId=38811226326b8, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投稿后Under Review ,一周后编辑拒稿，不适合本刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a06490553, createdName=ms7000000422843528, createdTime=Tue Jun 14 09:11:12 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889704, encodeId=be63889e046f, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫;肝病 经验分享：7月底投稿，9月21日修回，10月1日接收，各位加油，超过9页的部分每页花100英镑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Fri Oct 02 15:04:19 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889629, encodeId=05c7889629f6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肝病;免疫 经验分享：超过9页100英镑一页，一个半月修回，10后天接收，英文综述。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Thu Oct 01 23:55:19 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肝病 ; 临床 经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601794, encodeId=9602601e942d, content=请问杂志审稿系统里的Ja是什么意思啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7ae3080608, createdName=Annie2333, createdTime=Mon Jun 08 11:46:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2148260, encodeId=dcef214826006, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3天送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47245509838, createdName=ms9000001010544398, createdTime=Sun Jul 16 09:22:36 CST 2023, time=2023-07-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0 经验分享：跟楼上一个哥们挺像，综述投了一个半月，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：中科院大类一区TOP期刊，一篇临床回顾性文章，2020-03-18日投稿，2020-05-07日收到一审意见，major revision，2个审稿人，第一个审稿人意见比较多，对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题，几个单词写作的小问题。2020-05-17修回，2020-06-09返回意见，reject with hope，因为第一个审稿人有两个问题回答不好，让继续作出解释，第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查，再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回，2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格，希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]

2023-09-04 ms4000002019232997 来自湖北省

这个杂志投稿之后很快就变成under review状态，有两个编辑名字，这是送外审了还是编辑初审啊？

43 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2156049, encodeId=ced021560498b, content=这个杂志投稿之后很快就变成under review状态，有两个编辑名字，这是送外审了还是编辑初审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e57d5450113, createdName=ms4000002019232997, createdTime=Mon Sep 04 16:33:05 CST 2023, time=2023-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交 10-10 拒稿 第一个审稿人完全否定 第二个审稿人列出了大量的建议 副主编也给出了一条建议 总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226326, encodeId=38811226326b8, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投稿后Under Review ,一周后编辑拒稿，不适合本刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a06490553, createdName=ms7000000422843528, createdTime=Tue Jun 14 09:11:12 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889704, encodeId=be63889e046f, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫;肝病 经验分享：7月底投稿，9月21日修回，10月1日接收，各位加油，超过9页的部分每页花100英镑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Fri Oct 02 15:04:19 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889629, encodeId=05c7889629f6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肝病;免疫 经验分享：超过9页100英镑一页，一个半月修回，10后天接收，英文综述。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Thu Oct 01 23:55:19 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肝病 ; 临床 经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601794, encodeId=9602601e942d, content=请问杂志审稿系统里的Ja是什么意思啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7ae3080608, createdName=Annie2333, createdTime=Mon Jun 08 11:46:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2148260, encodeId=dcef214826006, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3天送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47245509838, createdName=ms9000001010544398, createdTime=Sun Jul 16 09:22:36 CST 2023, time=2023-07-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0 经验分享：跟楼上一个哥们挺像，综述投了一个半月，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：中科院大类一区TOP期刊，一篇临床回顾性文章，2020-03-18日投稿，2020-05-07日收到一审意见，major revision，2个审稿人，第一个审稿人意见比较多，对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题，几个单词写作的小问题。2020-05-17修回，2020-06-09返回意见，reject with hope，因为第一个审稿人有两个问题回答不好，让继续作出解释，第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查，再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回，2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格，希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]

2021-10-15 YJJJJJ

9-7 提交
10-10 拒稿
第一个审稿人完全否定
第二个审稿人列出了大量的建议
副主编也给出了一条建议
总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投.

79 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2156049, encodeId=ced021560498b, content=这个杂志投稿之后很快就变成under review状态，有两个编辑名字，这是送外审了还是编辑初审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e57d5450113, createdName=ms4000002019232997, createdTime=Mon Sep 04 16:33:05 CST 2023, time=2023-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交 10-10 拒稿 第一个审稿人完全否定 第二个审稿人列出了大量的建议 副主编也给出了一条建议 总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226326, encodeId=38811226326b8, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投稿后Under Review ,一周后编辑拒稿，不适合本刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a06490553, createdName=ms7000000422843528, createdTime=Tue Jun 14 09:11:12 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889704, encodeId=be63889e046f, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫;肝病 经验分享：7月底投稿，9月21日修回，10月1日接收，各位加油，超过9页的部分每页花100英镑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Fri Oct 02 15:04:19 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889629, encodeId=05c7889629f6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肝病;免疫 经验分享：超过9页100英镑一页，一个半月修回，10后天接收，英文综述。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Thu Oct 01 23:55:19 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肝病 ; 临床 经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601794, encodeId=9602601e942d, content=请问杂志审稿系统里的Ja是什么意思啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7ae3080608, createdName=Annie2333, createdTime=Mon Jun 08 11:46:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2148260, encodeId=dcef214826006, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3天送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47245509838, createdName=ms9000001010544398, createdTime=Sun Jul 16 09:22:36 CST 2023, time=2023-07-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0 经验分享：跟楼上一个哥们挺像，综述投了一个半月，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：中科院大类一区TOP期刊，一篇临床回顾性文章，2020-03-18日投稿，2020-05-07日收到一审意见，major revision，2个审稿人，第一个审稿人意见比较多，对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题，几个单词写作的小问题。2020-05-17修回，2020-06-09返回意见，reject with hope，因为第一个审稿人有两个问题回答不好，让继续作出解释，第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查，再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回，2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格，希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]

2022-06-14 ms7000000422843528

投稿命中率:25.0
偏重的研究方向：肿瘤
经验分享：投稿后Under Review ,一周后编辑拒稿，不适合本刊

59 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2156049, encodeId=ced021560498b, content=这个杂志投稿之后很快就变成under review状态，有两个编辑名字，这是送外审了还是编辑初审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e57d5450113, createdName=ms4000002019232997, createdTime=Mon Sep 04 16:33:05 CST 2023, time=2023-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交 10-10 拒稿 第一个审稿人完全否定 第二个审稿人列出了大量的建议 副主编也给出了一条建议 总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226326, encodeId=38811226326b8, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投稿后Under Review ,一周后编辑拒稿，不适合本刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a06490553, createdName=ms7000000422843528, createdTime=Tue Jun 14 09:11:12 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889704, encodeId=be63889e046f, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫;肝病 经验分享：7月底投稿，9月21日修回，10月1日接收，各位加油，超过9页的部分每页花100英镑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Fri Oct 02 15:04:19 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889629, encodeId=05c7889629f6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肝病;免疫 经验分享：超过9页100英镑一页，一个半月修回，10后天接收，英文综述。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Thu Oct 01 23:55:19 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肝病 ; 临床 经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601794, encodeId=9602601e942d, content=请问杂志审稿系统里的Ja是什么意思啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7ae3080608, createdName=Annie2333, createdTime=Mon Jun 08 11:46:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2148260, encodeId=dcef214826006, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3天送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47245509838, createdName=ms9000001010544398, createdTime=Sun Jul 16 09:22:36 CST 2023, time=2023-07-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0 经验分享：跟楼上一个哥们挺像，综述投了一个半月，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：中科院大类一区TOP期刊，一篇临床回顾性文章，2020-03-18日投稿，2020-05-07日收到一审意见，major revision，2个审稿人，第一个审稿人意见比较多，对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题，几个单词写作的小问题。2020-05-17修回，2020-06-09返回意见，reject with hope，因为第一个审稿人有两个问题回答不好，让继续作出解释，第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查，再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回，2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格，希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]

2020-10-02 민민

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：免疫;肝病
经验分享：7月底投稿，9月21日修回，10月1日接收，各位加油，超过9页的部分每页花100英镑。

168 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2156049, encodeId=ced021560498b, content=这个杂志投稿之后很快就变成under review状态，有两个编辑名字，这是送外审了还是编辑初审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e57d5450113, createdName=ms4000002019232997, createdTime=Mon Sep 04 16:33:05 CST 2023, time=2023-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交 10-10 拒稿 第一个审稿人完全否定 第二个审稿人列出了大量的建议 副主编也给出了一条建议 总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226326, encodeId=38811226326b8, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投稿后Under Review ,一周后编辑拒稿，不适合本刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a06490553, createdName=ms7000000422843528, createdTime=Tue Jun 14 09:11:12 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889704, encodeId=be63889e046f, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫;肝病 经验分享：7月底投稿，9月21日修回，10月1日接收，各位加油，超过9页的部分每页花100英镑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Fri Oct 02 15:04:19 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889629, encodeId=05c7889629f6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肝病;免疫 经验分享：超过9页100英镑一页，一个半月修回，10后天接收，英文综述。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Thu Oct 01 23:55:19 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肝病 ; 临床 经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601794, encodeId=9602601e942d, content=请问杂志审稿系统里的Ja是什么意思啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7ae3080608, createdName=Annie2333, createdTime=Mon Jun 08 11:46:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2148260, encodeId=dcef214826006, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3天送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47245509838, createdName=ms9000001010544398, createdTime=Sun Jul 16 09:22:36 CST 2023, time=2023-07-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0 经验分享：跟楼上一个哥们挺像，综述投了一个半月，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：中科院大类一区TOP期刊，一篇临床回顾性文章，2020-03-18日投稿，2020-05-07日收到一审意见，major revision，2个审稿人，第一个审稿人意见比较多，对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题，几个单词写作的小问题。2020-05-17修回，2020-06-09返回意见，reject with hope，因为第一个审稿人有两个问题回答不好，让继续作出解释，第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查，再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回，2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格，希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]

2020-10-01 민민

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：肝病;免疫
经验分享：超过9页100英镑一页，一个半月修回，10后天接收，英文综述。

136 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2156049, encodeId=ced021560498b, content=这个杂志投稿之后很快就变成under review状态，有两个编辑名字，这是送外审了还是编辑初审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e57d5450113, createdName=ms4000002019232997, createdTime=Mon Sep 04 16:33:05 CST 2023, time=2023-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交 10-10 拒稿 第一个审稿人完全否定 第二个审稿人列出了大量的建议 副主编也给出了一条建议 总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226326, encodeId=38811226326b8, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投稿后Under Review ,一周后编辑拒稿，不适合本刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a06490553, createdName=ms7000000422843528, createdTime=Tue Jun 14 09:11:12 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889704, encodeId=be63889e046f, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫;肝病 经验分享：7月底投稿，9月21日修回，10月1日接收，各位加油，超过9页的部分每页花100英镑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Fri Oct 02 15:04:19 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889629, encodeId=05c7889629f6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肝病;免疫 经验分享：超过9页100英镑一页，一个半月修回，10后天接收，英文综述。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Thu Oct 01 23:55:19 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肝病 ; 临床 经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601794, encodeId=9602601e942d, content=请问杂志审稿系统里的Ja是什么意思啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7ae3080608, createdName=Annie2333, createdTime=Mon Jun 08 11:46:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2148260, encodeId=dcef214826006, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3天送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47245509838, createdName=ms9000001010544398, createdTime=Sun Jul 16 09:22:36 CST 2023, time=2023-07-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0 经验分享：跟楼上一个哥们挺像，综述投了一个半月，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：中科院大类一区TOP期刊，一篇临床回顾性文章，2020-03-18日投稿，2020-05-07日收到一审意见，major revision，2个审稿人，第一个审稿人意见比较多，对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题，几个单词写作的小问题。2020-05-17修回，2020-06-09返回意见，reject with hope，因为第一个审稿人有两个问题回答不好，让继续作出解释，第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查，再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回，2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格，希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]

2021-04-23 Yi wen

审稿速度:3.0 | 投稿命中率:25.0
偏重的研究方向：肝病 ; 临床
经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。

91 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2156049, encodeId=ced021560498b, content=这个杂志投稿之后很快就变成under review状态，有两个编辑名字，这是送外审了还是编辑初审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e57d5450113, createdName=ms4000002019232997, createdTime=Mon Sep 04 16:33:05 CST 2023, time=2023-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交 10-10 拒稿 第一个审稿人完全否定 第二个审稿人列出了大量的建议 副主编也给出了一条建议 总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226326, encodeId=38811226326b8, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投稿后Under Review ,一周后编辑拒稿，不适合本刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a06490553, createdName=ms7000000422843528, createdTime=Tue Jun 14 09:11:12 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889704, encodeId=be63889e046f, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫;肝病 经验分享：7月底投稿，9月21日修回，10月1日接收，各位加油，超过9页的部分每页花100英镑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Fri Oct 02 15:04:19 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889629, encodeId=05c7889629f6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肝病;免疫 经验分享：超过9页100英镑一页，一个半月修回，10后天接收，英文综述。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Thu Oct 01 23:55:19 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肝病 ; 临床 经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601794, encodeId=9602601e942d, content=请问杂志审稿系统里的Ja是什么意思啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7ae3080608, createdName=Annie2333, createdTime=Mon Jun 08 11:46:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2148260, encodeId=dcef214826006, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3天送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47245509838, createdName=ms9000001010544398, createdTime=Sun Jul 16 09:22:36 CST 2023, time=2023-07-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0 经验分享：跟楼上一个哥们挺像，综述投了一个半月，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：中科院大类一区TOP期刊，一篇临床回顾性文章，2020-03-18日投稿，2020-05-07日收到一审意见，major revision，2个审稿人，第一个审稿人意见比较多，对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题，几个单词写作的小问题。2020-05-17修回，2020-06-09返回意见，reject with hope，因为第一个审稿人有两个问题回答不好，让继续作出解释，第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查，再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回，2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格，希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]

2020-06-08 Annie2333

请问杂志审稿系统里的Ja是什么意思啊？

133 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2156049, encodeId=ced021560498b, content=这个杂志投稿之后很快就变成under review状态，有两个编辑名字，这是送外审了还是编辑初审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e57d5450113, createdName=ms4000002019232997, createdTime=Mon Sep 04 16:33:05 CST 2023, time=2023-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交 10-10 拒稿 第一个审稿人完全否定 第二个审稿人列出了大量的建议 副主编也给出了一条建议 总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226326, encodeId=38811226326b8, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投稿后Under Review ,一周后编辑拒稿，不适合本刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a06490553, createdName=ms7000000422843528, createdTime=Tue Jun 14 09:11:12 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889704, encodeId=be63889e046f, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫;肝病 经验分享：7月底投稿，9月21日修回，10月1日接收，各位加油，超过9页的部分每页花100英镑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Fri Oct 02 15:04:19 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889629, encodeId=05c7889629f6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肝病;免疫 经验分享：超过9页100英镑一页，一个半月修回，10后天接收，英文综述。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Thu Oct 01 23:55:19 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肝病 ; 临床 经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601794, encodeId=9602601e942d, content=请问杂志审稿系统里的Ja是什么意思啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7ae3080608, createdName=Annie2333, createdTime=Mon Jun 08 11:46:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2148260, encodeId=dcef214826006, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3天送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47245509838, createdName=ms9000001010544398, createdTime=Sun Jul 16 09:22:36 CST 2023, time=2023-07-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0 经验分享：跟楼上一个哥们挺像，综述投了一个半月，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：中科院大类一区TOP期刊，一篇临床回顾性文章，2020-03-18日投稿，2020-05-07日收到一审意见，major revision，2个审稿人，第一个审稿人意见比较多，对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题，几个单词写作的小问题。2020-05-17修回，2020-06-09返回意见，reject with hope，因为第一个审稿人有两个问题回答不好，让继续作出解释，第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查，再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回，2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格，希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]

2023-07-16 ms9000001010544398 来自福建省

审稿速度:3.0 | 投稿命中率:25.0
经验分享：3天送审

39 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2156049, encodeId=ced021560498b, content=这个杂志投稿之后很快就变成under review状态，有两个编辑名字，这是送外审了还是编辑初审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e57d5450113, createdName=ms4000002019232997, createdTime=Mon Sep 04 16:33:05 CST 2023, time=2023-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交 10-10 拒稿 第一个审稿人完全否定 第二个审稿人列出了大量的建议 副主编也给出了一条建议 总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226326, encodeId=38811226326b8, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投稿后Under Review ,一周后编辑拒稿，不适合本刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a06490553, createdName=ms7000000422843528, createdTime=Tue Jun 14 09:11:12 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889704, encodeId=be63889e046f, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫;肝病 经验分享：7月底投稿，9月21日修回，10月1日接收，各位加油，超过9页的部分每页花100英镑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Fri Oct 02 15:04:19 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889629, encodeId=05c7889629f6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肝病;免疫 经验分享：超过9页100英镑一页，一个半月修回，10后天接收，英文综述。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Thu Oct 01 23:55:19 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肝病 ; 临床 经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601794, encodeId=9602601e942d, content=请问杂志审稿系统里的Ja是什么意思啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7ae3080608, createdName=Annie2333, createdTime=Mon Jun 08 11:46:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2148260, encodeId=dcef214826006, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3天送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47245509838, createdName=ms9000001010544398, createdTime=Sun Jul 16 09:22:36 CST 2023, time=2023-07-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0 经验分享：跟楼上一个哥们挺像，综述投了一个半月，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：中科院大类一区TOP期刊，一篇临床回顾性文章，2020-03-18日投稿，2020-05-07日收到一审意见，major revision，2个审稿人，第一个审稿人意见比较多，对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题，几个单词写作的小问题。2020-05-17修回，2020-06-09返回意见，reject with hope，因为第一个审稿人有两个问题回答不好，让继续作出解释，第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查，再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回，2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格，希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]

2020-09-07 ms4000000689346681

审稿速度:2.0
经验分享：跟楼上一个哥们挺像，综述投了一个半月，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。

150 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2156049, encodeId=ced021560498b, content=这个杂志投稿之后很快就变成under review状态，有两个编辑名字，这是送外审了还是编辑初审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e57d5450113, createdName=ms4000002019232997, createdTime=Mon Sep 04 16:33:05 CST 2023, time=2023-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交 10-10 拒稿 第一个审稿人完全否定 第二个审稿人列出了大量的建议 副主编也给出了一条建议 总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226326, encodeId=38811226326b8, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投稿后Under Review ,一周后编辑拒稿，不适合本刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a06490553, createdName=ms7000000422843528, createdTime=Tue Jun 14 09:11:12 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889704, encodeId=be63889e046f, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫;肝病 经验分享：7月底投稿，9月21日修回，10月1日接收，各位加油，超过9页的部分每页花100英镑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Fri Oct 02 15:04:19 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889629, encodeId=05c7889629f6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肝病;免疫 经验分享：超过9页100英镑一页，一个半月修回，10后天接收，英文综述。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=민민, createdTime=Thu Oct 01 23:55:19 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肝病 ; 临床 经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601794, encodeId=9602601e942d, content=请问杂志审稿系统里的Ja是什么意思啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7ae3080608, createdName=Annie2333, createdTime=Mon Jun 08 11:46:07 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2148260, encodeId=dcef214826006, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3天送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47245509838, createdName=ms9000001010544398, createdTime=Sun Jul 16 09:22:36 CST 2023, time=2023-07-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0 经验分享：跟楼上一个哥们挺像，综述投了一个半月，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：中科院大类一区TOP期刊，一篇临床回顾性文章，2020-03-18日投稿，2020-05-07日收到一审意见，major revision，2个审稿人，第一个审稿人意见比较多，对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题，几个单词写作的小问题。2020-05-17修回，2020-06-09返回意见，reject with hope，因为第一个审稿人有两个问题回答不好，让继续作出解释，第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查，再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回，2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格，希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]

2020-08-30 Dr.？？？

审稿速度:6.0 | 投稿命中率:25.0
经验分享：中科院大类一区TOP期刊，一篇临床回顾性文章，2020-03-18日投稿，2020-05-07日收到一审意见，major revision，2个审稿人，第一个审稿人意见比较多，对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题，几个单词写作的小问题。2020-05-17修回，2020-06-09返回意见，reject with hope，因为第一个审稿人有两个问题回答不好，让继续作出解释，第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查，再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回，2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格，希望杂志分数越来越高。

3 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务